U.S. REITS Stock News

Saia (SAIA) has been drawing attention after recent share price moves, with the stock last closing at US$396.74. Investors are weighing this performance against its recent returns and current business fundamentals. See our latest analysis for Saia. That recent 23.6% 1 month share price return and 17.7% year to date share price return point to building momentum, while the 1 year total shareholder return of 16.5% reflects a more measured longer term outcome. If Saia's move has you thinking...

MercadoLibre (NasdaqGS:MELI) plans a major investment in Brazil for 2026 to expand its logistics and e-commerce operations. The plan includes 14 new fulfillment centers across the country. The company expects to hire about 10,000 employees as part of this expansion. The 2026 spending plan is about 50% higher than MercadoLibre's prior year outlay in Brazil. For you as an investor, this move highlights how central Brazil is to MercadoLibre's e-commerce and fintech ecosystem in Latin America...

Why Globe Life is on investors’ radar now Globe Life (GL) has drawn attention after recent share price moves, with the stock last closing at $147.55. Investors are weighing this level against the insurer’s current financial profile and return history. See our latest analysis for Globe Life. The recent 1-month share price return of 6.57% and 6.60% year to date sits alongside a 1-year total shareholder return of 22.75%, which points to momentum building rather than fading for Globe Life. If you...

If you are wondering whether Applied Materials at US$395.73 is still reasonably priced after a strong run, you are not alone. The stock has recorded returns of 11.7% over the last 7 days, 15.9% over 30 days, 47.2% year to date and 174.5% over the past year, which naturally raises questions about risk, reward and where value stands today. Recent coverage has focused on Applied Materials as a key player in semiconductor equipment, with investors closely watching how industry demand and capital...

CVS Health and the Federal Trade Commission have reached a proposed settlement related to insulin pricing practices involving CVS subsidiaries Caremark and Zinc Health Services. The consent agreement is designed to resolve complaints tied to the company’s pharmacy benefit manager activities in the insulin market. The settlement, once finalized, would address a key regulatory issue that has been affecting CVS Health’s PBM operations. For investors tracking NYSE:CVS, this regulatory...

In April 2026, Tapcheck announced a fully embedded integration with Paychex HR PEO, enabling eligible employees to access a portion of their earned wages instantly via the Tapcheck app or a Tapcheck Mastercard, without requiring payroll teams to adopt new systems or processes. This move highlights how Paychex is using real-time payroll and machine-learning-based balance calculations to broaden financial wellness tools for clients in complex staffing industries such as hospitality and senior...

If you are wondering whether Pinterest is starting to look attractively priced or still has more downside risk, its recent share performance gives you a lot to think about. The stock closed at US$18.02, with returns of a 1.3% decline over 7 days, a 0.9% decline over 30 days, a 32.2% decline year to date and a 30.3% decline over the past year, which may have shifted how the market views its potential. These moves have played out alongside ongoing user interest in visual search and shopping...

In April 2026, DXC Technology expanded its long-standing collaboration with ServiceNow and introduced new AI-powered Assure Smart Apps for insurers, aiming to modernize operations with modular, workflow-driven tools that can be deployed without overhauling core systems. By acting as ServiceNow’s “Customer Zero” for its Core Business Suite while simultaneously packaging those AI capabilities into pre-integrated insurance solutions, DXC is positioning itself as both an early enterprise adopter...

Goldman Sachs Group (NYSE:GS) reported first quarter profit that was 19% higher year over year. Global Banking & Markets delivered record revenues in the period. Management pointed to growth in investment banking fees, AI initiatives, and private credit as key contributors. ...........................................................The bank completed its acquisition of Innovator Capital Management, expanding its ETF platform and active fund offering. For investors tracking large global...

Context for Coterra Energy’s recent share performance Coterra Energy (CTRA) has drawn attention after recent share moves, including a 1 day return of around a 1.2% decline and a 4.8% decline over the past week, alongside stronger gains over the past month and the past 3 months. See our latest analysis for Coterra Energy. Zooming out, the recent share price pullback sits against a stronger backdrop, with a 24.1% year to date share price return and a 35.37% 1 year total shareholder return that...

Recent insider activity at Q2 Holdings (QTWO) has attracted attention, with nearly US$23 million of shares sold over the past three months and no insider buying. This has prompted questions about alignment between management and shareholders. See our latest analysis for Q2 Holdings. At a share price of US$47.98, Q2 Holdings has seen a 4.60% 1 day share price gain but a 90 day share price return decline of 30.27%, alongside a 36.40% 1 year total shareholder return decline and a very large 3...

Recently, SLB announced that its OneSubsea joint venture won a high-pressure, high-temperature multiphase boosting contract for Beacon Offshore’s Shenandoah deepwater field in the Gulf of America, alongside a long-term collaboration framework with PETRONAS Suriname and Subsea7 for integrated subsea developments in Suriname. These agreements underline how SLB’s advanced subsea and digital capabilities are being written into multi-year offshore development plans, potentially reinforcing the...

FDA grants Priority Review to ifinatamab deruxtecan, a B7-H3 antibody drug conjugate co-developed by Merck (NYSE:MRK) and Daiichi Sankyo. The filing covers adults with extensive-stage small cell lung cancer whose disease has relapsed after chemotherapy. If approved, this would be the first B7-H3 targeted medicine available for any cancer. For investors watching NYSE:MRK, this Priority Review highlights fresh momentum in Merck’s oncology pipeline alongside its existing cancer portfolio. The...

Rumors emerged that Nvidia is exploring an acquisition of a major PC manufacturer, with speculation centering on Dell Technologies (NYSE:DELL). The report suggested a potential deal that could link Nvidia's chips with a large PC and server footprint. Nvidia later denied pursuing any such acquisition, but the initial headlines coincided with a sharp move higher in Dell's share price. Dell Technologies sits at the intersection of PCs, servers, storage and enterprise solutions, which places it...

Wondering whether Gilead Sciences at around US$139 a share still offers value or if most of the opportunity is already reflected in the price, this article breaks that question down in plain terms. The stock shows a mixed recent picture, with a 0.2% return over the last 7 days, a 4.1% decline over 30 days, a 14.3% return year to date and a 35.1% return over 1 year that some investors may read as a strong payoff for sticking with the name. Recent coverage has focused on how Gilead Sciences...

In March 2026, West Pharmaceutical Services opened a new 165,000 square foot building at its Damastown, Dublin site, expanding contract services to include advanced automation and commercial-scale drug-handling capabilities for high-volume treatments such as diabetes and obesity therapies. This expansion deepens the West Vantage single-source offering across development, manufacturing, packaging, and regulatory support, aiming to streamline customers' paths from concept to commercial supply...

If you have been wondering whether Revvity is starting to look interesting on price, this breakdown will help you make sense of where the value case currently stands. Revvity shares last closed at US$92.64, after returns of 4.9% over the past week and 8.3% over the past month, while the year to date return is a 5.6% decline and the 1 year return is a 4.8% decline. These recent moves sit against a longer record that includes a 31.3% decline over 3 years and a 30.4% decline over 5 years, which...

Oklo (NYSE:OKLO) expects its first reactor to reach operational criticality by July 4. Criticality would mean achieving a self-sustaining nuclear reaction in the company’s initial microreactor. This milestone is important for moving Oklo’s advanced microreactor technology toward commercial use. Oklo focuses on advanced microreactors designed to provide compact nuclear power solutions. For investors watching the nuclear and clean energy space, this expected criticality event marks a shift in...

MediWound Ltd. recently announced that Vericel, its exclusive North American distributor for NexoBrid, secured a ten-year BARDA contract worth up to US$197 million to fund NexoBrid procurement, vendor-managed inventory, potential U.S. manufacturing, and development of new indications and formulations. The contract’s mix of immediate stockpile purchases, inventory services, and longer-term development funding highlights how government preparedness priorities can underpin Vericel’s burn-care...

If you are wondering whether Dollar Tree is attractively priced after a volatile few years, this article walks through how its current share price stacks up against several valuation checks. The stock closed at US$102.13, with returns of an 8.1% decline over 7 days, a 5.0% decline over 30 days, a 20.0% decline year to date, but 38.6% over 1 year, highlighting how quickly sentiment around value and risk can shift. Recent coverage has focused on Dollar Tree's repositioning within value retail...

Why Autohome is on investors’ radar today Autohome (NYSE:ATHM) is drawing attention after a period of mixed share performance, with the stock showing a small move over the past week but weaker returns over the past month and past 3 months. See our latest analysis for Autohome. At a share price of $17.85, Autohome’s 7 day share price return of 2.12% sits against a weaker backdrop, with a 30 day share price return of 5.36% and a 1 year total shareholder return decline of 26.91%, suggesting...

Wondering if Brink's at around US$106.84 is still offering value or if the easy money has already been made? This article walks through what the current price might imply about expectations baked into the stock. Over the past year the share price has returned 23.0%, with a 3.1% gain over the last 7 days, a roughly flat 30 day move at 0.2% decline, and a 8.3% decline year to date, which may catch the eye of investors thinking about risk and entry points. Recent headlines around Brink's have...

If you are wondering whether Micron Technology's current share price still offers value after a big run, this breakdown will help you frame what you are really paying for. The stock last closed at US$426.56, with returns of 13.0% over 7 days, 0.1% over 30 days, 35.2% year to date, and a very large return over 1 year and 3 years. This naturally raises questions about what is already priced in and how risk has shifted. Recent coverage has focused on Micron as a key beneficiary of interest in...

Wondering if American Superconductor at around US$37.81 is still offering value or if you are arriving late to the story? This article walks through what the current price might imply for you as a shareholder or potential buyer. The stock has posted returns of 15.9% over 7 days, 21.9% over 30 days and 19.7% year to date, with 108.0% over 1 year and a very large gain over 3 years that is around 7x. Those moves can quickly change how comfortable you feel about the current valuation and future...